Journal
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 22, Issue 2, Pages 110-120Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/jop.2006.22.110
Keywords
-
Categories
Funding
- NEI NIH HHS [R01 EY10659, R01 EY09171] Funding Source: Medline
Ask authors/readers for more resources
The aim of this study was to investigate the modulation of efflux mechanisms using transporter-targeted prodrug derivatization of a model P-gp substrate, quinidine. The L-valine, L-valine-valine esters of quinidine, val-quinidine (VQ), and val-val-quinidine (VVQ) were synthesized in our laboratory, respectively. [C-14] erythromycin was chosen to delineate the affinity of quinidine (Q) toward p-gp. [H-3] glycylsarcosine (GS, or glysar) was chosen as a model peptide transporter (PEPT) substrate. Uptake studies were performed on rPCEC (rabbit primary corneal epithelial culture) using 12-well plates. Transport studies were conducted with isolated rabbit corneas at 34 degrees C. Efflux of [C-14] erythromycin was significantly increased in the presence of quinidine, whereas it was unaltered in the presence of VQ and VVQ. VVQ was more stable, both in buffers and tissue homogenate. Transport of VQ and VVQ was inhibited with GS, and their permeability values were 1.5 and 3 times higher than the permeability of quinidine, respectively. Results from this study clearly indicate that prodrug derivatization of quinidine can modulate P-gp-mediated efflux. These prodrugs have a reduced or diminished affinity toward P-gp and were further recognized by the peptide transporter-mediated process. Enhanced permeabilities of the prodrugs indicate that drug derivatization can be a viable strategy for overcoming P-gp-mediated efflux.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available